Research Progress on Immunotherapy in Triple-Negative Breast Cancer

Triple-negative breast cancer is a kind of breast cancer with negative estrogen receptor and progesterone receptor, and low expression of human epidermal growth factor receptor-2. Compared with other subtypes of breast cancer, triple-negative breast cancer has the characteristics of strong invasive potential, high recurrence rate and poor prognosis. It is one of the most intractable types of breast cancer. At present, there is a lack of effective treatment. As a new clinical treatment, immunotherapy has great clinical significance for the treatment of triplenegative breast cancer, and provides new treatment options for patients. The present article reviews the research progresses of immunotherapy for triple-negative breast cancer in recent years. The main contents cover the molecular classification, active immunotherapy, passive immunotherapy, oncolytic immunotherapy, and the prospect of immunotherapy for triple-negative breast cancer.